0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Research Letters |

The FDA and New Safety Warnings FREE

Thomas J. Moore, AB; Sonal Singh, MD, MPH; Curt D. Furberg, MD, PhD
[+] Author Affiliations

Author Affiliations: Institute for Safe Medication Practices, Alexandria, Virginia (Mr Moore); Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland (Dr Singh); and Division of Public Health Sciences, Wake Forest University School of Medicine, Winston-Salem, North Carolina (Dr Furberg).


Arch Intern Med. 2012;172(1):78-80. doi:10.1001/archinternmed.2011.618.
Text Size: A A A
Published online

In response to postmarket drug safety surveillance and research data, the US Food and Drug Administration (FDA) and drug manufacturer may take 1 of 2 types of action. In extreme cases the FDA may remove a drug from the market. More often the product label or package insert is revised to reflect newly discovered risks. The most clinically significant new information is added to 1 of 3 legally defined sections of the prescribing information1: (1) a boxed warning (information that is essential to be considered when prescribing the drug); (2) a contraindication (clinical situations when a drug's risks clearly outweigh its benefits); and (3) a warning (adverse reactions with reasonable evidence of a causal association, reactions that may require discontinuation, or reactions that interfere with a laboratory test).

We analyzed 1 calendar year of these major label changes to provide insights into this safety program. We report the number of actions, severity of events, and nature and scope of the safety information. We also describe the types of drugs affected, whether they were recently approved drugs or established treatments, and what type and level of scientific evidence was used to support of these label changes.

Major safety regulatory actions during 2009 were defined as drug withdrawals for safety, new or revised boxed warnings, contraindications, or warnings for approved prescription drugs.2 For each action we calculated the years since initial drug approval and identified the brand name or generic status. We categorized the cited evidence source (ie, clinical trial, meta-analysis, epidemiological study, adverse event report). We also evaluated whether the scientific evidence was derived directly from studies of the target drug or inferred from studies of other drugs either with similar chemical structure and mechanism of action or that were indicated for use in the same patient population. A complete description of the study methods is available in the eAppendix.

In 2009, the FDA approved 181 major safety regulatory actions, including 1 drug safety withdrawal, 25 new boxed warnings, 19 new contraindications, 90 new warnings, and 46 revisions of previous actions (Table). Among the newly identified adverse effects were suicidal behavior, life-threatening viral infections, renal failure, and increased cancer risk in children. Adverse event reports from drug manufacturers or through the MedWatch program were the predominant source of scientific information and formed the basis of 77 of 135 new regulatory actions (57%) and 19 of 25 new boxed warnings (76%). Clinical studies were cited as the evidence source for 26 of 135 actions (19%) but only 2 were derived from statistically significant differences and 1 was based on a single study case. A large FDA meta-analysis of suicidal behavior and antiepileptic drugs generated warnings for 19 drugs.3 In 23 of 135 new actions (17%), the scientific evidence was derived from other drugs, with 15 based on similar chemical structure and mechanism, and 8 based on the same indication and/or patient population. The safety actions occurred a median of 11 years after initial approval and included 61 drugs marketed for 15 years or more; only 36 actions involved drugs within first 5 years after approval.

Table Graphic Jump LocationTable. Boxed Warnings, Contraindications, and Warnings in 2009

These major safety regulatory actions disclose clinically significant risks of widely used drugs, typically many years after approval. Scientific evidence cited to alert physicians about new risks for marketed drugs used notably less rigorous methods than the well-controlled, blinded, and randomized clinical trials used to document benefit prior to approval. When reported adverse events supported the warning, little or no detail was provided about the number and type of reports relied on or any systematic analysis performed.

Some of the most extensive changes involved class warnings applied to a group of drugs without distinguishing between them. All drugs indicated for epilepsy treatment got the same suicidal behavior warning, even those not included in the meta-analysis and drugs with markedly different mechanisms of action. The class warning was extended to 1 benzodiazepine—clonazepam (Klonopin; F. Hoffmann-La Roche Ltd) with an indication in epilepsy treatment—but not to other benzodiazepines. In another case the FDA announced and put similar suicidal behavior and violence warnings on 2 smoking cessation treatments—varenicline (Chantix; Pfizer Inc) and bupropion hydrochloride (Zyban; GlaxoSmithKline)—even though the FDA's unpublished but publicly available studies revealed that varenicline accounted for 10 times as many reports as bupropion and had higher risks.4,5

The 11-year median time since approval for actions in this 1-year study was markedly higher than the 7 years reported in a 2002 study of boxed warnings or withdrawals since 1975.6 Improving postmarket drug safety requires timelier ascertainment of drug risks together with higher quality and better documented scientific evidence.

Correspondence: Mr Moore, Institute for Safe Medication Practices, 101 N Columbus St, Ste 410, Alexandria, VA 22414 (tmoore@ismp.org).

Author Contributions:Study concept and design: Moore, Singh, and Furberg. Acquisition of data: Moore and Singh. Analysis and interpretation of data: Moore, Singh, and Furberg. Drafting of the manuscript: Moore and Singh. Critical revision of the manuscript for important intellectual content: Moore, Singh, and Furberg. Statistical analysis: Moore and Singh. Study supervision: Furberg.

Financial Disclosure: None reported.

US Food and Drug Administration. Guidance for Industry: US Food and Drug Administration.  Warnings and Precautions, Contraindications, and Boxed Warning Sections of Labeling for Human Prescription Drugs and Biological Products—Content and Format (Draft Guidance). Silver Spring, MD: US Food and Drug Administration; 2006
 Drug Safety Labeling Changes. US Food and Drug Administration Web site. http://www.fda.gov/Safety/MedWatch/SafetyInformation/Safety-RelatedDrugLabelingChanges/default.htm. Accessed July 24, 2011
 Safety Alerts for Human Medical Products > Antiepileptic Drugs. US Food and Drug Administration Web site. 2009. http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm074939.htm. Accessed October 13, 2011
Pollock M, Mosholder A. Suicidality: Varenicline; Bupropion; Nicotine Transdermal Patch. Silver Spring, MD: US Food and Drug Administration, Center for Drug Evaluation and Research; 2008
Pollock M. AERS Crude Counts of Psychiatric Adverse Events, Accidental Injuries, Angioedema, and Serious Skin Reactions: Varenicline; NDA 21928; Pfizer Inc Bupropion (Zyban); NDA 20711; GlaxoSmithKline. Silver Spring, MD: US Food and Drug Administration, Center for Drug Evaluation and Research; 2009
Lasser KE, Allen PD, Woolhandler SJ, Himmelstein DU, Wolfe SM, Bor DH. Timing of new black box warnings and withdrawals for prescription medications.  JAMA. 2002;287(17):2215-2220
PubMed   |  Link to Article

Figures

Tables

Table Graphic Jump LocationTable. Boxed Warnings, Contraindications, and Warnings in 2009

References

US Food and Drug Administration. Guidance for Industry: US Food and Drug Administration.  Warnings and Precautions, Contraindications, and Boxed Warning Sections of Labeling for Human Prescription Drugs and Biological Products—Content and Format (Draft Guidance). Silver Spring, MD: US Food and Drug Administration; 2006
 Drug Safety Labeling Changes. US Food and Drug Administration Web site. http://www.fda.gov/Safety/MedWatch/SafetyInformation/Safety-RelatedDrugLabelingChanges/default.htm. Accessed July 24, 2011
 Safety Alerts for Human Medical Products > Antiepileptic Drugs. US Food and Drug Administration Web site. 2009. http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm074939.htm. Accessed October 13, 2011
Pollock M, Mosholder A. Suicidality: Varenicline; Bupropion; Nicotine Transdermal Patch. Silver Spring, MD: US Food and Drug Administration, Center for Drug Evaluation and Research; 2008
Pollock M. AERS Crude Counts of Psychiatric Adverse Events, Accidental Injuries, Angioedema, and Serious Skin Reactions: Varenicline; NDA 21928; Pfizer Inc Bupropion (Zyban); NDA 20711; GlaxoSmithKline. Silver Spring, MD: US Food and Drug Administration, Center for Drug Evaluation and Research; 2009
Lasser KE, Allen PD, Woolhandler SJ, Himmelstein DU, Wolfe SM, Bor DH. Timing of new black box warnings and withdrawals for prescription medications.  JAMA. 2002;287(17):2215-2220
PubMed   |  Link to Article

Correspondence

CME
Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.
NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).
Submit a Comment

Multimedia

Some tools below are only available to our subscribers or users with an online account.

Web of Science® Times Cited: 10

Related Content

Customize your page view by dragging & repositioning the boxes below.

Articles Related By Topic
Related Topics
PubMed Articles